Effect of Infliximab Treatment on QT Intervals in Patients With Ankylosing Spondylitis


Senel S. , Cobankara V., Taskoylu O., Guclu A., Evrengul H., Kaya M. G.

JOURNAL OF INVESTIGATIVE MEDICINE, cilt.59, ss.1273-1275, 2011 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 59 Konu: 8
  • Basım Tarihi: 2011
  • Dergi Adı: JOURNAL OF INVESTIGATIVE MEDICINE
  • Sayfa Sayıları: ss.1273-1275

Özet

Background: Cardiovascular complications are one of the most common and the most serious extraskeletal manifestations of ankylosing spondylitis (AS). Infliximab, a monoclonal antibody against tumor necrosis factor, is widely used in the treatment of AS. QT dispersion (QTd), which relates to left ventricular function and is used as an index of cardiac dysrhythmia, may be useful as a prognostic guide. Early detection of possible cardiac involvement may not be clinically evident, whereas it may be detected by electrocardiography.